Sollzo announces rewards of 4.2% for earning on MRNA stock! | Sollzo Ltd

Sollzo announces rewards of 4.2% for earning on MRNA stock!

SOLLZO's profit on Moderna shares increased by 6467.16% compared to the same period last year.

Dear Investors!

SOLLZO Profit on Moderna (MRNA) Stock Soars 65x!

Moderna reported second-quarter 2021 revenue of $ 4.4 billion, up from $ 67 million in the same period last year, an increase of 6,467.16%.

SOLLZO owns a significant stake in MRNA and, on the occasion of the high profit, announces the payment of a bonus to the users of its investment platform.

For each new deposit in the Sollzo online project on all plans, a remuneration of 4.2% of the deposit amount will be accrued, and the net profit for the selected investment plan will increase by the same percentage.

Offer valid until 12:00:00 GMT (GMT) on August 17, 2021.


The main increase in Moderna's revenue came from the sale of the coronavirus vaccine, which is currently licensed for emergency use in several countries. What's more, grants under an agreement with the Biomedical Advanced Research and Development Authority (“BARDA”) for the development of the COVID-19 vaccine have also boosted revenues.

Moderna delivered 302 million doses of mRNA-1273, including 199 million doses in the second quarter, worldwide in the first half of 2021. The company expects to produce 800 million to 1 billion doses in 2021 and 2 to 3 billion doses in 2022.

During the August contract negotiations with the European Union, Moderna, like Pfizer, raised the price of the COVID-19 vaccine by 35%, which will also boost SOLLZO's profits.

These factors guarantee a stable financial position of SOLLZO in the long term and provide a high income for the company and our investors.

Get consistent, high returns on high-value assets at the intersection of two powerful and dynamic industries - healthcare and real estate.
By investing with SOLLZO, you are investing in your well-being!